CME/CNE/CPE Medical Education Program Helps Physicians Integrate the FDA Mycophenolate Safety Standards to Prevent Potential Birth Defects
Leading continuing medical education provider, Rockpointe, in conjunction with Boston University and Potomac Center for Medical Education is offering webinars and an on-demand web course on mycophenolate safety standards to help prevent birth defects when prescribing mycophenolic acid (MPA) products, including mycophenolate mofetil (MMF) (CellCept) and enteric-coated mycophenolate sodium (Myfortic). This continuing medical education program is offered at no cost to all clinicians who prescribe mycophenolates.
Mycophenolates were approved by the FDA in 1995 and 2004 as immunosuppressants used in preventing rejection of transplanted organs. MPA has become a front-line anti-rejection therapy in combination with calcineurin-inhibitors and corticosteroids. Mycophenolates are also widely used in the treatment of a wide range of autoimmune conditions such as lupus, rheumatoid arthritis, and multiple sclerosis.
However, use of MPA during pregnancy is associated with a significant increased risk of pregnancy loss, congenital malformations, and low birth weight. The FDA approved the Mycophenolate Shared System Risk Evaluation and Mitigation Strategy (MREMS) in 2012, but despite the information provided to clinicians and patients on the pregnancy risks associated with the use of MPA, pregnancies remain too common in patients being treated with MPAs, leading to preventable adverse pregnancy outcomes.
Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes will provide HCPs who prescribe MPAs with information on MPA-associated pregnancy risks, the need for counseling female patients of reproductive potential on birth control and planning, and the need for reporting pregnancies to the Mycophenolate Pregnancy Registry. It will also provide information to female patients of reproductive potential who are prescribed MPA about the pregnancy risks and the importance of appropriate planning and birth control.
A live webinar is scheduled for:
Monday, November 8, 2021
8:30 – 9:30 PM ET (7:30 – 8:30 PM CT / 6:30 – 7:30 PM MT / 5:30 – 6:30 PM PT)
There is no fee for this educational activity. To receive credit, participants must register, participate in the one-hour-long activity, complete the online post-test with a score of at least 70%, and complete the online evaluation. Participants are allowed to take the post-test multiple times.
For more information and to register for this activity, click here.
An on-demand webcourse will be available on www.rockpointe.com in the near future.
Physician Accreditation and Credit Designation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Boston University School of Medicine designates this live activity material/booklet for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email cme@bu.edu.
Nursing Accreditation Statement
This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly provided by the Potomac Center for Medical Education and Rockpointe.
Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Contact Hours: 1.0 of which 1.0 are eligible for pharmacology credit.
For questions regarding CE credit or the evaluation, please email cme@bu.edu.
Pharmacist Accreditation Statement
The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hours (0.10 CEUs) of continuing education credit. UAN Number: 0418-9999-21-004-L05-P.
This is an application activity.
For questions regarding CPE credit or the evaluation please contact cme@potomacme.org
This activity is jointly provided by the Boston School of Medicine, Potomac Center for Medical Education, and Rockpointe.
This activity is supported by an independent medical education grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combating the national opioid crisis and the COVID-19 pandemic, recognizing issues with vaping, and utilizing technical advances in care. As part of its commitment to quality, Rockpointe works to inform the continuing education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.